Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 7/2015

01-07-2015 | Original Research Article

Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?

Authors: Pieter M. M. De Kesel, Willy E. Lambert, Christophe P. Stove

Published in: Clinical Pharmacokinetics | Issue 7/2015

Login to get access

Abstract

Background and Objective

Although metabolite-to-parent drug concentration ratios in hair have been suggested as a possible tool to study the metabolism of drugs in a non-invasive way, no studies are available that evaluated this in a systematic way. Cytochrome P450 (CYP) 1A2 is a drug-metabolizing enzyme characterized by large inter-individual differences in its activity. The standard approach for CYP1A2 phenotyping is to determine the paraxanthine/caffeine ratio in plasma at a fixed timepoint after intake of a dose of the CYP1A2 substrate caffeine. The aim of this study was to evaluate whether paraxanthine/caffeine ratios measured in hair samples reflect the plasma-based CYP1A2 phenotype.

Methods

Caffeine and paraxanthine concentrations were measured in proximal 3 cm segments of hair samples from 60 healthy volunteers and resulting paraxanthine/caffeine ratios were correlated with CYP1A2 phenotyping indices in plasma.

Results

Paraxanthine/caffeine ratios in hair ranged from 0.12 to 0.93 (median 0.41); corresponding ratios in plasma ranged from 0.09 to 0.95 (median 0.40). A statistically significant correlation was found between ratios in hair and plasma (r = 0.41, p = 0.0011). However, large deviations between ratios in both matrices were found in individual cases. Although the influence of several factors on paraxanthine/caffeine ratios and hair–plasma deviations was investigated, no evident factors explaining the observed variability could be identified.

Conclusion

The variability between hair and plasma ratios complicates the interpretation of hair paraxanthine/caffeine ratios on an individual basis and, therefore, compromises their practical usefulness as alternative CYP1A2 phenotyping matrix.
Appendix
Available only for authorised users
Literature
1.
Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006;370(1–2):17–49.PubMedCrossRef
2.
Barbosa J, Faria J, Carvalho F, Pedro M, Queriós O, Moreira R, et al. Hair as an alternative matrix in bioanalysis. Bioanalysis. 2013;5(8):895–914.PubMedCrossRef
3.
Agius R, Kintz P. Guidelines for European workplace drug and alcohol testing in hair. Drug Test Anal. 2010;2(8):367–76.PubMedCrossRef
4.
Madry MM, Rust KY, Guglielmello R, Baumgartner MR, Kraemer T. Metabolite to parent drug concentration ratios in hair for the differentiation of tramadol intake from external contamination and passive exposure. Forensic Sci Int. 2012;223(1–3):330–4.PubMedCrossRef
5.
De Kesel PM, Lambert WE, Stove CP. The role of (bio)markers in hair analysis. In: Stove CP, editor. New sampling strategies in toxicology and therapeutic drug monitoring. London: Future Science (in press).
6.
Thieme D, Rolf B, Sachs H, Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med. 2008;122(2):149–55.PubMedCrossRef
7.
Eisenhut M, Thieme D, Schmid D, Fieseler S, Sachs H. Hair analysis for determination of isoniazid concentrations and acetylator phenotype during antituberculous treatment. Tuberc Res Treat. 2012;2012:327027.PubMedCentralPubMed
8.
LeMasters GK, Khurana Hershey GH, Sivaprasad V, Martin LJ, Pilipenko V, Ericksen MB, et al. N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth control cohort. Pharmacogenomics J. 2014. doi:10.​1038/​tpj.​2014.​44.PubMed
9.
Koren G, Blanchette P, Lubetzky A, Kramer M. Hair nicotine:cotinine metabolic ratio in pregnant women: a new method to study metabolism in late pregnancy. Ther Drug Monit. 2008;30(2):246–8.PubMedCrossRef
10.
O’Brien L, Baumer C, Thieme D, Sachs H, Koren G. Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach. Forensic Sci Int. 2010;196(1–3):93–6.PubMedCrossRef
11.
Himes SK, Goodwin RS, Rock CM, Jones HE, Johnson RE, Wilkins DG, et al. Methadone and metabolites in hair of methadone-assisted pregnant women and their infants. Ther Drug Monit. 2012;34(3):337–44.PubMedCentralPubMedCrossRef
12.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.PubMedCrossRef
13.
Shirley KL, Hon YY, Penzak SR, Lam YWF, Spratlin V, Jann MW. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology. 2003;28:961–6.PubMed
14.
Özdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol. 2001;21(4):398–407.PubMedCrossRef
15.
Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica. 1999;29(8):847–57.PubMedCrossRef
16.
Zhang Z, Fasco MJ, Huong Z, Guengerich FP, Kaminsky LS. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Dispos. 1995;23(12):1339–46.PubMed
17.
Perera V, Gross AS, McLachlan AJ. Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr Drug Metab. 2012;13(5):667–78.PubMedCrossRef
18.
Kalow W, Tang BK. The use of caffeine for enzyme assays—a critical appraisal. Clin Pharmacol Ther. 1993;53(5):503–14.PubMedCrossRef
19.
Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther. 2007;81(2):270–83.PubMedCrossRef
20.
De Kesel PM, Lambert WE, Stove CP. Why dried blood spots are an ideal tool for CYP1A2 phenotyping. Clin Pharmacokinet. 2014;53(8):763–71.PubMedCrossRef
21.
Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011;63(9):1161–8.PubMedCrossRef
22.
De Kesel PM, Lambert WE, Stove CP. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma. Bioanalysis. 2014;6(22):3011–24.PubMedCrossRef
23.
24.
25.
Mizuno A, Uematsu T, Gotoh S, Katoh E, Nakashima M. The measurement of caffeine concentration in scalp hair as an indicator of liver function. J Pharm Pharmacol. 1996;48(6):660–4.PubMedCrossRef
26.
27.
Crettol S, de Leon J, Hiemke C, Eap CP. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther. 2014;95(3):254–7.PubMedCrossRef
28.
LeBeau M, Montgomery MA, Brewer JD. The role of variations in growth rate and sample collection on interpreting results of segmental analyses of hair. Forensic Sci Int. 2011;210(1–3):110–6.PubMedCrossRef
29.
Simon T, Becquemont L, Hamon B, Nouyrigat E, Chodjania Y, Poirier JM, et al. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharm. 2001;52(5):601–4.CrossRef
30.
Henderson GL. Mechanisms of drug incorporation into hair. Forensic Sci Int. 1993;63(1–3):19–29.PubMedCrossRef
31.
Kronstrand R, Förstberg-Peterson S, Kågedal B, Ahlner J, Larson G. Codeine concentration in hair after oral administration of dependent on melanin content. Clin Chem. 1999;45(9):1485–94.PubMed
32.
Villain M, Chèze M, Tracqui A, Ludes B, Kintz P. Windows of detection of zolpidem in urine and hair: application to two drug facilitated sexual assaults. Forensic Sci Int. 2004;143(2–3):157–61.PubMedCrossRef
33.
Jurado C, Kintz P, Menéndez M, Repetto M. Influence of the cosmetic treatment of hair on drug testing. Int J Legal Med. 1997;110(3):159–63.PubMedCrossRef
34.
Dussy F, Carson N, Hangartner S, Briellmann T. Is one hair lock really representative? Drug Test Anal. 2014;6(1):5–8.PubMedCrossRef
35.
Perera V, Gross AS, McLachlan AJ. Influence of environmental and genetic factors on CYP1A2 activity of South Asian and European ancestry. Clin Pharmacol Ther. 2012;92(4):511–9.PubMed
36.
Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9(2):131–44.PubMed
Metadata
Title
Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
Authors
Pieter M. M. De Kesel
Willy E. Lambert
Christophe P. Stove
Publication date
01-07-2015
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 7/2015
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-015-0237-7

Other articles of this Issue 7/2015

Clinical Pharmacokinetics 7/2015 Go to the issue

Original Research Article

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus

Original Research Article

Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor

Original Research Article

Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor

Original Research Article

Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement

Review Article

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

Review Article

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir